巴雷特食管演变为食管腺癌的研究进展

doi:10.3969/j.issn.2095-378X.2020.02.009

外科研究与新技术 ›› 2020, Vol. 9 ›› Issue (2): 100-104.doi: 10.3969/j.issn.2095-378X.2020.02.009

巴雷特食管演变为食管腺癌的研究进展

姚莉雯, 许树长

同济大学附属同济医院消化科,上海 200065

收稿日期:2020-04-22 出版日期:2020-06-28 发布日期:2020-09-16
通讯作者: 许树长,电子信箱：xschang@163.com
作者简介:姚莉雯(1983—）,女,硕士,主治医师,从事消化内科工作

Reseach progress on development of Barrett esophagus to esophageal adenocarcinoma

YAO Liwen, XU Shuchang

Department of Gastroenterology, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, China

Received:2020-04-22 Online:2020-06-28 Published:2020-09-16

摘要/Abstract

摘要： 巴雷特食管（Barrett esophagus,BE）是指食管下段的正常复层鳞状上皮被化生的柱状上皮所取代。BE是食管腺癌（esophageal adenocarcinoma,EAC）的癌前病变。而从BE到EAC的演变和进展成为BE研究的焦点,诸多的关键信号因子及信号途径参与其中。本文就BE如何演变为EAC的研究进展作一综述。

关键词: 巴雷特食管, 食管腺癌, 发病机制, 信号通路

Abstract: Barrett esophagus (BE) refers to the replacement of normal lamellar squamous epithelium in the lower esophagus by metaplasia of columnar epithelium. BE is the strongest risk for esophageal adenocarcinoma (EAC). The evolution and progression from BE to EAC has become the research focus of BE. Many key signaling factors and signaling pathways are involved. This paper reviewed the research progress on how BE evolves into EAC.

Key words: Barrett esophagus, Esophageal adenocarcinoma, Pathogenesis, Signaling pathway

中图分类号:

R735.1

姚莉雯, 许树长. 巴雷特食管演变为食管腺癌的研究进展[J]. 外科研究与新技术, 2020, 9(2): 100-104.

YAO Liwen, XU Shuchang. Reseach progress on development of Barrett esophagus to esophageal adenocarcinoma[J]. Surgical Research and New Technique, 2020, 9(2): 100-104.

参考文献

[1] Ross-Innes C S, Becq J, Warren A, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma[J].Nat Genet, 2015,47(9):1038-1046.
[2] Weaver J M J, Ross-Innes C S, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis[J].Nat Genet,2014,46(8):837-843.
[3] Stachler M D, Camarda N D, Deitrick C, et al.Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma[J].Gastroenterology,2018,155(1):156-167.
[4] Guo X, Tang Y, Zhu W.Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns[J].BMC Genomics,2018,19(1):769.
[5] Horvath B, Singh P, Xie H, et al.Expression of P53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett’s esophagus and epithelial changes indefinite for dysplasia[J].Gastroenterol Rep (Oxf),2016,4(4):304-309.
[6] Kastelein F, Biermann K, Steyerberg E W, et al.Aberrant P53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus[J].Gut,2013,62(12):1676-1683.
[7] Yan H P, Roberts L J, Davies S S, et al.Isolevuglandins as a gauge of lipid peroxidation in human tumors[J].Free Radic Biol Med,2017,106(5):62-68.
[8] Pretto G, Gurski R R, Binato M, et al.Increase of epidermal growth factor receptor expression in progression of GERD,Barrett and adenocarcinoma of esophagus[J].Dig Dis Sci,2013,58(1):115-122.
[9] Kim J, Bowlby R, Mungall A, et al.Integrated genomic characterization of oesophageal carcinoma[J].Nature,2017,541(7636):169-175.
[10] Xiong D D, He R Q, Lan A H, et al. Clinical significances of p27 in digestive tract cancers:a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data[J].Oncotarget, 2018, 9(15):12284‐12303.
[11] Alves-Fernandes D K, Jasiulionis M G. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer[J].Int J Mol Sci,2019,20(13):3153.
[12] Majka J, Wierdak M, Szlachcic A, et al.Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-γ system in experimental rat Barrett’s esophagus[J].Am J Physiol Gastrointest Liver Physiol,2020,318(3):G375-G389.
[13] Haque S, Morris J C.Transforming growth factor-β: A therapeutic target for cancer[J].Hum Vaccin Immunother,2017,13(8):1741-1750.
[14] Lee S W, Lien H C, Lin C C, et al.Low expression of transforming growth factor β in the epithelium of Barrett’s esophagus[J].Gastroenterology Res,2018,11(3):189-194.
[15] Wang D H, Tiwari A, Kim M E, et al. Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett’s metaplasia[J].Clin Invest, 2014, 124(9): 3767‐3780.
[16] Gibson M K, Zaidi A H, Davison J M, et al. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease[J].Ann Surg,2013,258(1):82‐88.
[17] Götzel K, Chemnitzer O, Maurer L, et al.In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett’s sequence[J].BMC Gastroenterol,2019,19(1):38.
[18] Grewal U S, Randhawa M S, Mehta A.Role of mitochondrial markers in improved detection and risk-stratification in Barrett’s esophagus patients[J].Yale J Biol Med,2019,92(3):533-539.
[19] Phelan J J, Mac Carthy F, Feighery R, et al.Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett’s oesophagus[J].Cancer Lett,2014,354(1):122-131.
[20] Varghese S, Newton R, Ross-Innes C S, et al. Analysis of dysplasia in patients with Barrett’s esophagus based on expression pattern of 90 genes[J].Gastroenterology,2015,149(6):1511-1518.

巴雷特食管演变为食管腺癌的研究进展

Reseach progress on development of Barrett esophagus to esophageal adenocarcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

[1]	王安凤, 潘晨, 童晓文. TLR4/MyD88信号通路在卵巢癌紫杉醇化疗抵抗中的研究进展[J]. 外科研究与新技术, 2019, 8(1): 49-53.
[2]	王超兰, 朱天民. 腰椎术后骶髂关节源性下腰痛发病机制及临床治疗[J]. 外科研究与新技术, 2018, 7(1): 61-64.
[3]	王大鹏吴一芳海舰. 生物信息学在阿尔茨海默病发病机制和药物设计中的应用[J]. 外科研究与新技术, 2016, 5(1): 53-56.
[4]	JIBRIL Khalif diriye JIBRIL Khalif diriye. 硫氯双酚通过JNK通路诱导人胶质瘤细胞凋亡的体外实验研究[J]. 外科研究与新技术, 2015, 4(3): 158-162.
[5]	周永新单颖军. 原发性自发性气胸发病机制及复发原因的研究进展[J]. 外科研究与新技术, 2015, 4(1): 52-56.
[6]	于涛, 俞光荣. 一种潜在的骨肉瘤治疗靶向—TWEAK/Fn14信号通路[J]. 外科研究与新技术, 2013, 2(1): 62-65.